**Protocol for the Examination of Resection Specimens From Patients With Primary Carcinoma of the Vagina**

**Version:** 4.3.0.1

**Protocol Posting Date:** November 2021

**CAP Laboratory Accreditation Program Protocol Required Use Date:** March 2022

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

**For accreditation purposes, this protocol should be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Resection | Includes vaginectomy |
| **Tumor Type** | **Description** |
| Carcinoma | Includes squamous cell carcinoma, adenocarcinoma and variants, carcinosarcoma, adenosarcoma, neuroendocrine carcinoma, mixed epithelial – neuroendocrine tumors, and germ cell tumors |

**This protocol is NOT required for accreditation purposes for the following:**

|  |
| --- |
| **Procedure** |
| Biopsy (consider Vagina Biopsy protocol) |
| Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy) |
| Cytologic specimens |

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols) |
| Sarcoma other than adenosarcoma (consider the Soft Tissue protocol) |
| Melanoma (consider using the cutaneous Melanoma protocol) |

**Authors**

Uma G. Krishnamurti, MD, PhD\*; Barbara A. Crothers, DO\*; Lara R. Harik, MD\*; Christopher N. Otis, MD; George G. Birdsong, MD; Saeid Movahedi-Lankarani, MD; Veronica Klepeis, MD, PhD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.  
\* Denotes primary author.

**Accreditation Requirements**

This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

* Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
* Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
* Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

**Synoptic Reporting**

All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

* Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
* The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
* Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  + Anatomic site or specimen, laterality, and procedure
  + Pathologic Stage Classification (pTNM) elements
  + Negative margins, as long as all negative margins are specifically enumerated where applicable
* The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

**Summary of Changes**

**v 4.3.0.1**

* The CAP made no changes to Cancer Protocol content. We updated metadata only for the electronic Cancer Checklists (eCC), requiring a version number change for the Word and PDF Cancer Protocols.

**Reporting Template**

**Protocol Posting Date: November 2021**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (VAGINA: Resection)**

**Standard(s)**: AJCC-UICC 8, FIGO Cancer Report 2018

**SPECIMEN (Note** [**A**](#2099)**)**

**Procedure**

\_\_\_ Local excision

\_\_\_ Partial vaginectomy

\_\_\_ Radical vaginectomy

\_\_\_ Trachelectomy

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**TUMOR**

**Tumor Site (select all that apply)**

\_\_\_ Vagina, upper third: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Vagina, middle third: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Vagina, lower third: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Vagina, not otherwise specified: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Size**

\_\_\_ Greatest dimension in Centimeters (cm): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

**+Additional Dimension in Centimeters (cm): \_\_\_\_ x \_\_\_\_ cm**

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Histologic Type (Note** [**B**](#2100)**)**

\_\_\_ Squamous cell carcinoma, HPV-associated

\_\_\_ Squamous cell carcinoma, HPV-independent

\_\_\_ Squamous cell carcinoma, NOS

\_\_\_ Adenocarcinoma, NOS

\_\_\_ Adenocarcinoma, HPV-associated

\_\_\_ Adenocarcinoma, Skene, Cowper and Littre gland origin

\_\_\_ Mucinous carcinoma, NOS

\_\_\_ Mucinous carcinoma, gastric type

\_\_\_ Mucinous carcinoma, intestinal type

\_\_\_ Endometrioid carcinoma

\_\_\_ Clear cell carcinoma

\_\_\_ Mesonephric adenocarcinoma

\_\_\_ Adenosquamous carcinoma

\_\_\_ Adenoid basal carcinoma

\_\_\_ Small cell neuroendocrine carcinoma

\_\_\_ Large cell neuroendocrine carcinoma

\_\_\_ Combined small cell neuroendocrine carcinoma

\_\_\_ Combined large cell neuroendocrine carcinoma

\_\_\_ Neuroendocrine tumor, NOS

\_\_\_ Undifferentiated carcinoma

\_\_\_ Mixed tumor NOS

\_\_\_ Carcinosarcoma

\_\_\_ Adenosarcoma

\_\_\_ Germ cell tumor (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Histologic Grade (Note** [**C**](#2101)**)**

\_\_\_ G1, well differentiated

\_\_\_ G2, moderately differentiated

\_\_\_ G3, poorly differentiated

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ GX, cannot be assessed: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Site(s) Involved by Direct Tumor Extension (select all that apply)**

*Any organ not selected is either not involved or was not submitted.*

\_\_\_ Confined to vaginal wall

\_\_\_ Involves subepithelial soft tissue

\_\_\_ Involves the muscular wall

\_\_\_ Paravaginal tissues

\_\_\_ Pelvic sidewall

\_\_\_ Vagina, lower third

\_\_\_ Bladder mucosa#

\_\_\_ Rectal mucosa#

\_\_\_ Site(s) beyond true pelvis (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other organs / tissue (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

*# Mucosal surface of bladder or rectum must be involved*

**Lymphovascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**MARGINS**

**Margin Status for Invasive Carcinoma**

*# High-grade squamous intraepithelial lesion (VaIN 2-3) or adenocarcinoma in situ (AIS) should be reported if present, even if margin is involved by invasive carcinoma.*

\_\_\_ All margins negative for invasive carcinoma#

**+Closest Margin(s) to Invasive Carcinoma (select all that apply)**

\_\_\_ Peripheral (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Deep (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Distance from Invasive Carcinoma to Closest Margin**

*Specify in Millimeters (mm)*

\_\_\_ Exact distance: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Greater than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ At least: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Less than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Less than 1 mm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Invasive carcinoma present at margin

**Margin(s) Involved by Invasive Carcinoma (select all that apply)**

\_\_\_ Peripheral (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Deep (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**Margin Status for HSIL (VaIN 2-3) or AIS (select all that apply)**

\_\_\_ All margins negative for high-grade squamous intraepithelial lesion (HSIL) and / or adenocarcinoma in situ (AIS)

\_\_\_ High-grade squamous intraepithelial lesion (HSIL) present at margin

**+Margin(s) Involved by HSIL (select all that apply)**

\_\_\_ Peripheral (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Adenocarcinoma in situ (AIS) present at margin

**+Margin(s) Involved by AIS (select all that apply)**

\_\_\_ Peripheral (specify location, if possible): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

**+Margin Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**REGIONAL LYMPH NODES**

**Regional Lymph Node Status**

*# For the upper two-thirds of the vagina, the following are considered regional lymph nodes: pelvic NOS, parametrial, obturator, internal iliac (hypogastric), external iliac, common iliac, sacral, presacral, and para-aortic lymph nodes. For the lower third of the vagina, the following are considered regional lymph nodes: inguinal and femoral lymph nodes. Any involved non-regional nodes should be categorized as metastases (pM1) with a comment in the distant metastasis section. Presence of isolated tumor cells no greater than 0.2 mm in regional lymph node(s) is considered N0(i+).*

\_\_\_ Not applicable (no regional lymph nodes submitted or found)

\_\_\_ Regional lymph nodes present

\_\_\_ All regional lymph nodes negative for tumor cells

\_\_\_ Tumor present in regional lymph node(s)

**Number of Nodes with Tumor (excluding isolated tumor cells)**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Number of Nodes with Isolated Tumor Cells (0.2 mm or less)#**

*# Reporting the number of lymph nodes with isolated tumor cells is required only in the absence of metastasis greater than 0.2 mm in other lymph nodes.*

\_\_\_ Not applicable

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Nodal Site(s) with Tumor (select all that apply)**

*Right lymph nodes*

\_\_\_ Right inguinal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right femoral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right pelvic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right parametrial: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right obturator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right internal iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right external iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right presacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right sacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right para-aortic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other right lymph nodes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Left lymph nodes*

\_\_\_ Left inguinal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left femoral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left pelvic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left parametrial: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left obturator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left internal iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left external iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left presacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left sacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left para-aortic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other left lymph nodes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Lymph nodes, laterality not specified*

\_\_\_ Inguinal, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Femoral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Pelvic, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Parametrial, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Obturator, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Internal iliac, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ External iliac, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Presacral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Sacral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Para-aortic, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Additional Lymph Node Findings (select all that apply)**

\_\_\_ None identified

\_\_\_ Extranodal extension

\_\_\_ Fixed / ulcerated nodes

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not applicable

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Number of Lymph Nodes Examined**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Nodal Site(s) Examined (select all that apply)**

*Right lymph nodes*

\_\_\_ Right inguinal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right femoral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right pelvic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right parametrial: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right obturator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right internal iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right external iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right presacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right sacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Right para-aortic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other right lymph nodes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Left lymph nodes*

\_\_\_ Left inguinal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left femoral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left pelvic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left parametrial: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left obturator: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left internal iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left external iliac: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left presacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left sacral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Left para-aortic: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other left lymph nodes (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Lymph nodes, laterality not specified*

\_\_\_ Inguinal, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Femoral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Pelvic, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Parametrial, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Obturator, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Internal iliac, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ External iliac, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Presacral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Sacral, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Para-aortic, NOS: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Regional Lymph Node Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**DISTANT METASTASIS**

**Distant Site(s) Involved, if applicable**

\_\_\_ Not applicable

\_\_\_ Specify site(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th ed.) (Note** [**D**](#2102)**)**

*Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.*

**TNM Descriptors (select all that apply)**

\_\_\_ Not applicable: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ m (multiple primary tumors)

\_\_\_ r (recurrent)

\_\_\_ y (post-treatment)

**pT Category**

\_\_\_ pT not assigned (cannot be determined based on available pathological information)

\_\_\_ pT0: No evidence of primary tumor

*pT1: Tumor confined to the vagina*

\_\_\_ pT1a: Tumor confined to the vagina, measuring less than or equal to 2.0 cm

\_\_\_ pT1b: Tumor confined to the vagina, measuring greater than 2.0 cm

\_\_\_ pT1 (subcategory cannot be determined)

*pT2: Tumor invading paravaginal tissues but not to pelvic sidewall*

\_\_\_ pT2a: Tumor invading paravaginal tissues but not to pelvic wall, measuring less than or equal to 2.0 cm

\_\_\_ pT2b: Tumor invading paravaginal tissues but not to pelvic wall, measuring greater than 2.0 cm

\_\_\_ pT2 (subcategory cannot be determined)

*# Pelvic sidewall is defined as the muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. On rectal examination, there is no cancer-free space between the tumor and pelvic sidewall. Tumor causing hydronephrosis or nonfunctioning kidney is an indirect indication of pelvic sidewall involvement*

\_\_\_ pT3: Tumor extending to the pelvic sidewall# and / or causing hydronephrosis or nonfunctioning kidney

*## Mucosal surface of bladder or rectum must be involved*

\_\_\_ pT4: Tumor invading the mucosa of the bladder or rectum## and / or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4)

**pN Category**

\_\_\_ pN not assigned (no nodes submitted or found)

\_\_\_ pN not assigned (cannot be determined based on available pathological information)

\_\_\_ pN0: No regional lymph node metastasis

\_\_\_ pN0(i+): Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm

\_\_\_ pN1: Pelvic or inguinal lymph node metastasis

**pM Category (required only if confirmed pathologically)**

\_\_\_ Not applicable - pM cannot be determined from the submitted specimen(s)

\_\_\_ pM1: Distant metastasis

**FIGO STAGE**

**+FIGO Stage (2018 FIGO Cancer Report)**

\_\_\_ I: Tumor of any size confined to the vagina

\_\_\_ II: Tumor of any size that invades paravaginal tissue but not the pelvic sidewall

\_\_\_ III: Tumor extends to the pelvic sidewall and / or involves the lower third of the vagina and / or causes hydronephrosis or nonfunctioning kidney or T1-T3 tumor involving pelvic or inguinal lymph nodes (N1) but not distant sites

\_\_\_ IV: Tumor extends beyond the true pelvis or involves the bladder and / rectal mucosa (bullous edema alone does not constitute stage IV)

\_\_\_ IVA: Tumor invades bladder and / or rectal mucosa and / or extends beyond the true pelvis, regardless of lymph node involvement (any N)

\_\_\_ IVB: Tumor of any size with spread to distant sites (M1), with or without involvement of adjacent structures (any T) or lymph nodes (any N)

**ADDITIONAL FINDINGS (Note** [**E**](#2103)**)**

**Additional Findings (select all that apply)**

\_\_\_ None identified

\_\_\_ High grade squamous intraepithelial lesion / vaginal intraepithelial neoplasia, grade 3 (VaIN3)

\_\_\_ High grade squamous intraepithelial lesion / vaginal intraepithelial neoplasia, grade 2 (VaIN2)

\_\_\_ Low grade squamous intraepithelial lesion / vaginal intraepithelial neoplasia, grade 1 (VaIN1)

\_\_\_ Condyloma acuminatum

\_\_\_ Adenocarcinoma in situ (AIS)

\_\_\_ Atypical adenosis

\_\_\_ Adenoma: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**SPECIAL STUDIES**

**+Ancillary Studies (specify) : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**+p16 Immunohistochemistry**

\_\_\_ Positive

\_\_\_ Negative

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. Procedure**

Local excision (wide local excision) is employed primarily for smaller lesions and should have margins surgically oriented. A partial vaginectomy leaves a portion of the vagina intact as a conduit to drain menses (if the uterus is retained). Radical (complete) vaginectomy removes the entire vagina and may be part of infralevatoric exenteration, radical hysterectomy and/or bilateral lymphadenectomy. Trachelectomy (removal of the lower portion of the cervix along with the upper vagina) may be employed when the cervix is involved for fertility-sparing. The peripheral margin is the tumor resection margin with mucosa and may be designated as proximal and distal (upper vaginal / lower vaginal). The deep margin is the tumor resection margin with soft tissue and may be designated as anterior, posterior, right or left lateral vaginal wall.   
  
Squamous cell carcinoma, the most frequent tumor, typically involves the posterior vagina, while adenocarcinoma almost exclusively involves the anterior vaginal wall. Both are most common in the upper 1/3 of the vagina.[1](#8024)

Prenatal DES Exposure

Prenatal exposure to diethylstilbestrol (DES) or related synthetic drugs was relatively common in the United States and other countries until 1971, when its relation to clear cell adenocarcinomas of the vagina and cervix led to proscription of these drugs by the Food and Drug Administration. From the 1970s to the turn of the 21 century, most patients with clear cell adenocarcinoma of the vagina had a history of DES exposure.[2](#8025) As this cohort ages, the diagnosis has been less common, and most women with this diagnosis currently have no DES exposure history. Furthermore, it has been reported that these patients have significantly worse outcomes than do patients with a history of DES exposure and patients with squamous cell carcinoma.[3](#8026) A bimodal age peak for DES-related carcinoma has, however, been reported, and therefore a history of this type of prenatal drug exposure should alert the pathologist to the possible presence of those tumors and associated lesions.[4,](#8027)[5](#8028)

Ectropion (erosion, eversion) of the cervix, which is characterized by the appearance of glandular (columnar) epithelium outside the external os of the cervix, is seen in approximately 90% of women exposed to DES in utero (but is often seen in unexposed women as well). Approximately one-third of patients exposed to DES have 1 or more gross structural abnormalities of the cervix.[2,](#8025)[5](#8028) The fallopian tubes are abnormal in some women exposed to DES in the form of hypoplasia or defects demonstrated on hysterosalpingographic examination.[5](#8028)

Third-generation exposure to DES is associated with decreased fertility, irregular menses, continued risk for clear cell adenocarcinoma, pregnancy mishaps such as preterm delivery, and psychosomatic disorders, indicating that DES adverse effects are genetically transmissible, possibly through epigenetics and transformation of protein 63 (TRP63.p63) that drives differentiation of Mullerian duct epithelium to squamous differentiation.[6,](#8029)[7,](#8030)[8](#8031)

Prior Tumors and Operations

A history of dysplasia, carcinoma in situ, or invasive carcinoma of the cervix, as well as knowledge of the tumor’s microscopic features, may be essential to determine whether a subsequent vaginal tumor is a recurrent or new tumor. Also, a history of a carcinoma higher in the female genital tract may influence the interpretation of a neoplasm that is detected in a specimen from the vagina. Prior pathology slides and reports should be obtained and reviewed if a review is deemed essential by the clinician or pathologist for optimal pathologic evaluation of the present specimen.

Clinical Findings and DES Exposure

Naked-eye examination, colposcopy, and iodine staining of the cervix and vagina may disclose a variety of changes highly suspicious of prenatal DES exposure, such as cervical hypoplasia, pseudopolyp, or coxcomb deformity, and vaginal adenosis or ridge, any of which should alert the pathologist to look carefully for DES changes.[5](#8028)

References

1. Lima M, Rio G, Horta M, Cunha TM. Primary vaginal malignancies: a single oncology centre experience. J Obstet Gynecol. 2019;39(6):827-832.
2. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-881.
3. Frank SJ, Deavers MT, Jhingran A, et al. Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol. 2007;105:470-474.
4. Hanselaar A, van Loosbroek M, Schuurbiers O, et al. Clear cell adenocarcinoma of the vagina and cervix: an update of the central Netherlands registry showing twin age incidence peaks. Cancer. 1997;79:2229-2236.
5. Kaufman RH, Noller K, Adam E, et al. Upper genital tract abnormalities and pregnancy outcome in diethylstilbestrol-exposed progeny. Am J Obstet Gynecol. 1984;148:973-984.
6. Clement R, Guilbaud E, Barrios L, Rouge-Maillart C, Jousset N, Rodat O. DES daughters in France: experts’ points of view on the various genital, uterine and obstetric pathologies, and in utero DES exposure. Med Sci Law. 2014;54(4):219-29.
7. Titus L, Hatch EE, Drake KM, et al. Reproductive and hormone-related outcomes in women whose mothers were exposed to in utero diethylstilbestrol (DES): a report from the UN National Cancer Institute DES Third Generation Study. Reprod Toxicol. 2019;84:32-38.
8. Laronda MM, Unno K, Butler LM, Kurita T. The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation. 2012;84(3):252-60.

**B. Histologic Type**

The protocol adheres to the standardized terminology proposed by the World Health Organization (WHO) classification of malignant and premalignant vaginal epithelial tumors.[1](#8036) This protocol is also used for adenosarcoma. The most common tumor subtype is squamous cell carcinoma. However, when such tumor simultaneously involves the cervix or the vulva and the vagina, the tumor is considered to originate from the cervix or vulva, with secondary extension to the vagina. Categorization of squamous cell carcinoma has been simplified into HPV-associated and HPV-independent types based upon their pathogenesis. If this association is unknown or unable to be determined, “not otherwise specified (NOS)” is appropriate. Former descriptive terms such as “warty”, “basaloid”, “verrucous” and “papillary” are no longer necessary components of the histologic type. Adjacent squamous intraepithelial lesions, the putative precursors, are a helpful clue to subtype. For HPV-associated precursors, low grade or high grade squamous intraepithelial lesion (SIL) is the preferred terminology but vaginal intraepithelial lesion (VaIN) may also be used, with appropriate grades 1, 2 or 3 (eg. VaIN2).  Microinvasive / superficially invasive carcinoma is not a recognized entity in the vagina, and thus the term is not used.

If adenocarcinoma is present in the vagina, it is important to remember that many of those tumors represent secondary involvement either by direct extension or metastases, most commonly from the endometrium, colorectum, ovary, vulva, urethra, or urinary bladder. Although rare, primary intestinal-type mucinous (adeno)carcinoma has been described in the vagina.[2,](#8037)[3](#8038) These tumors usually arise in a background of a benign adenomatous lesion or polyp. Awareness of this subtype is necessary to avoid misdiagnosis of a metastatic colorectal adenocarcinoma.[3,](#8038)[4,](#8039)[5](#8040) Primary gastric-type adenocarcinoma is also rare and usually associated with non-DES vaginal adenosis. The most differentiated form was previously known as “adenoma malignum” or “minimal deviation adenocarcinoma” but these tumors are now recognized as part of a spectrum of malignancy with gastric-type epithelium under the rubric of mucinous carcinoma, gastric-type. It has features identical to this entity in the cervix.[6,](#8041)[7](#8042) The tall columnar cells are characterized by abundant pale pink cytoplasm, distinct cell borders, basal nuclei and often minimal nuclear atypia, with immunoreactivity for MUC6 (more specific) and HIK1083, and mutation-type p53 patterns.[8](#8043) It is not associated with HPV or DES. p16 is block-like; ER and PR are generally nonreactive. Goblet and neuroendocrine cells may be present. Glandular patterns of invasion are subtle, typically lack stromal reaction, and are characterized by haphazardly arranged “claw-like” glands deep in the stroma, with focal or extensive glandular dilatation.[8](#8043)

The very rare adenocarcinoma of Skene gland origin mimics prostatic adenocarcinoma and is reactive with prostatic markers.[9](#8044) Equally rare is mesonephric adenocarcinoma, which is typically para-urethral and characterized by a diversity of architectural patterns within the tumor. They are presumed to arise from vaginal mesonephric remnants and thus are most often located in the lateral vaginal wall.[9,](#8044)[10](#8045)

Neuroendocrine tumor are extremely rare in the gynecologic tract other than ovary or cervix. The “combined” category must include the presence of a non-neuroendocrine carcinoma along with a neuroendocrine tumor.

References

1. Herrington CS, Kim K-R, Kong CS, McCluggage WG, Ordi J. Tumours of the vagina. In: WHO Classification of Tumours Editorial Board. Female genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2021 Jan 05]. (WHO classification of tumours series, 5th ed; vol 4). Available from <https://tumoursclassification.iarc.who.int/chpters/1>.
2. Tjalma WA, Colpaert CG. Primary vaginal adenocarcinoma of intestinal type arising from a tubulovillous adenoma. Int J Gynecol Cancer. 2006;16:1461-1465.
3. Ditto A, Martinelli F, Carcangiu ML, et al. Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. Int J Gynecol Pathol. 2007;26(4):490-493.
4. Mudhar HS, Smith JH, Tidy J. Primary vaginal adenocarcinoma of intestinal type arising from an adenoma: case report and review of the literature. Int J Gynecol Pathol. 2001;20:204-209.
5. Ditto A, Martinelli F, Carcangiu ML, et al. Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. Int J Gynecol Pathol. 2007;26:490-493.
6. Wong RW, Moore M, Talia KL, Ganesan R, McCluggage WG. Primary vaginal gastric-type adenocarcinoma and vaginal adenosis exhibiting gastric differentiation: report of a series with detailed immunohistochemical analysis. Am J Surg Pathol. 2018;42(7):958-970.
7. Carleton C, Hoang L, Sah S, et al. A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas. Am J Surg Pathol. 2016;40(5):636-44.
8. Talia KL, McCluggage WG. The developing spectrum of gastric-type cervical glandular lesions. Pathol. 2018;50(2):122-133.
9. Mueller I, Kametriser G, Jacobs VR, et al. Mesonephric adenocarcinoma of the vagina: diagnosis and multimodal treatment of a rare tumor and analysis of worldwide experience. Review. Strahlnther Onkol. 2016;192(9):668-671.
10. Mahasmej T, Alhamss S, Almusa Z, et al. Periurethral adenocarcinoma of mesonephric origin: a case report and review of the literature. Urol Case Rep. 2018;20:25-27.

**C. Histologic Grade**

A wide variety of grading systems, including some that evaluate only the extent of cellular differentiation and others that assess additional features such as the appearance of the tumor margin, the extent of inflammatory cell infiltration, and vascular invasion, have been used for squamous cell carcinoma of the cervix. However, there is no consensus emerging from the literature that any of these systems are reproducible or that they provide useful prognostic information. Similar problems arise with grading adenocarcinoma. Therefore, no specific grading system for vaginal cancers is recommended.

For the sake of uniformity, 3 grades may be used, as shown below, with the understanding that these have not been clinically validated. Grades 1 to 3 are assigned to carcinoma showing squamous or glandular differentiation; undifferentiated carcinoma is not graded (not applicable).

Grade X Cannot be assessed

Grade 1 Well differentiated

Grade 2 Moderately differentiated

Grade 3 Poorly differentiated

**D. Pathologic Stage Classification**

The TNM staging system of the American Joint Committee on Cancer (AJCC) for carcinoma of the vulva is recommended.[1,](#8049)[2](#8050) FIGO staging is desirable but optional.[3](#8051)

By AJCC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

**Additional Descriptors**

T Category Considerations

Lymphovascular Invasion (LVI) indicates whether microscopic lymphovascular invasion is identified.  LVI includes lymphatic invasion, vascular invasion, or lymphovascular invasion. By AJCC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

N Category Considerations

Regional lymph nodes in vaginal resections are based on vaginal lymphatic drainage. For the upper two-thirds of the vagina, the following are considered regional lymph nodes: pelvic, parametrial, obturator, internal iliac (hypogastric), external iliac, common iliac, sacral, presacral, and para-aortic. For the lower third of the vagina, the following are considered regional lymph nodes: inguinal and femoral. Any involved nonregional nodes should be categorized as metastases (pM1) with a comment on their location in the distant metastasis section.

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Reporting the number of lymph nodes with isolated tumor cells is required only in the absence of metastasis greater than 0.2 mm in other lymph nodes. Lymph nodes or distant sites with ITCs found by either histologic examination (eg, immunohistochemical evaluation for cytokeratin) or nonmorphological techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be so identified. There is currently no guidance in the literature as to how these patients should be coded; until more data are available, they should be coded as “N0(i+)” with a comment noting how the cells were identified.

Sentinel lymph node evaluation is undergoing investigation in early stage vaginal carcinoma but is not widely employed.[4,](#8052)[5,](#8053)[6](#8054) Sentinel nodes may be reported under “other, specify” with the site.

References

1. Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
2. Brierley JD, Gospodarowicz M, Wittekind Ch, eds. TNM Classification of Malignant Tumors. 8th ed. Oxford, UK: Wiley; 2016.
3. Bhatla N, Denny L. FIGO Cancer Report 2018. Int J Gynecol Obstet. 2018;142(Suppl 2):i-iv,1-158.
4. Skanjeti S, Dhomps A, Paschetta C, Tordo J, Giammarile F. Sentinel node mapping in gynecologic cancers: a comprehensive review. Semin Nucl Med. 2018;49(6):531-533.
5. Franklin ZCR, Tanner EJ. Where are we going with sentinel lymph node mapping in gynecologic cancers? Curr Oncol Rep. 2018;20(12):96.
6. Frumovitz M, Gayed IW, Jhingran A, et al. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008;108(3):478-481.

**E. Other Lesions**

Squamous dysplasia or carcinoma in situ, adenocarcinoma in situ, or atypical adenosis, particularly if such changes are at the resection margin, may increase the frequency of recurrent tumor. A few cases of primary invasive carcinoma of vagina have been reported to occur in association with severe vaginal prolapse.[1,](#8055)[2,](#8056)[3](#8057)

References

1. Iavazzo C, Vorgias G, Vecchini G, et al. Vaginal carcinoma in a completely prolapsed uterus: a case report. Arch Gynecol Obstet. 2007;275:503-505.
2. Batista TP, Morais JA, Reis TJ, et aI. A rare case of invasive vaginal carcinoma associated with vaginal prolapse. Arch Gynecol Obstet. 2009;280(5):845-848.
3. Gupta N, Mittal S, Dalmia S, et al. A rare case of primary invasive carcinoma of vagina associated with irreducible third degree uterovaginal prolapse. Arch Gynecol Obstet. 2007; 276:563-564.